Table 5.

Independent factors associated with the recurrence of HCC after DAA treatment in the early phase (within 1 year after DAA treatment completion) according to Cox proportional hazard model analysis

	Hazard ratio	95% CI	p-value
Post-treatment AFP (ng/mL)	1.056	1.026–1.087	< 0.001

Data are expressed as means ± standard deviation

ALT alanine aminotransferase; AST aspartate aminotransferase; AFP α-fetoprotein; eGFR estimated glomerular filtration rate; FIB-4 fibrosis-4; APRI AST to platelet ratio index; SVR sustained viral response; BCLC Barcelona Clinic Liver Cancer; CI confidence interval